89bio, Inc. (ETNB) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Francisco, CA, United States. वर्तमान CEO हैं Rohan Palekar.
ETNB के पास है IPO तिथि 2019-11-11, 93 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $2.2B.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
